Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms

Outcomes with “7+3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompted a phase 1/2 study (NCT02044796) of G-CSF, cladribine, high-dose cytarabine, and dose-escal...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpern, Anna B., Othus, Megan, Huebner, Emily M., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Gardner, Kelda M., Chen, Tara L., Buckley, Sarah A., Orlowski, Kaysey F., Anwar, Asma, Appelbaum, Frederick R., Erba, Harry P., Estey, Elihu H., Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192860/
https://www.ncbi.nlm.nih.gov/pubmed/29720734
http://dx.doi.org/10.1038/s41375-018-0135-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192860/
https://www.ncbi.nlm.nih.gov/pubmed/29720734
http://dx.doi.org/10.1038/s41375-018-0135-8

Ejemplares similares